Cerveau Technologies has inked a deal to license and supply AbbVie (NYSE:ABBV) with its [F-18]MK-6240 investigational tau imaging agent, the company said today.
After the FDA cleared the investigational new drug application for Cerveau’s imaging agent in June, the company said it planned to work with pharmaceutical partners to evaluate the product’s use in positron emission tomography scans to assess neurofibrillary tangles in the brain.
Get the full story at our sister site, Drug Delivery Business News.
The post Cerveau inks licensing deal with AbbVie for tau imaging agent appeared first on MassDevice.